Literature DB >> 14711437

Tumors of the conjunctiva and cornea.

Carol L Shields1, Jerry A Shields.   

Abstract

Tumors of the conjunctiva and cornea comprise a large and varied spectrum of conditions. These tumors are grouped into two major categories of congenital and acquired lesions. The acquired lesions are further subdivided based on origin of the mass into surface epithelial, melanocytic, vascular, fibrous, neural, histiocytic, myxoid, myogenic, lipomatous, lymphoid, leukemic, metastatic and secondary tumors. Melanocytic lesions include nevus, racial melanosis, primary acquired melanosis, melanoma, and other ocular surface conditions like ocular melanocytosis and secondary pigmentary deposition. The most frequent nonmelanocytic neoplastic lesions include squamous cell carcinoma and lymphoma, both of which have typical features appreciated on clinical examination. The caruncle displays a slightly different array of tumors compared to those elsewhere on the conjunctiva, as nevus and papilloma are most common, but oncocytoma and sebaceous gland hyperplasia, adenoma, and carcinoma can be found. In this report, we provide clinical description and illustration of the many conjunctival and corneal tumors and we discuss tumor management.

Entities:  

Mesh:

Year:  2004        PMID: 14711437     DOI: 10.1016/j.survophthal.2003.10.008

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  93 in total

1.  Conjunctival squamous cell neoplasia: the Liverpool Ocular Oncology Centre experience.

Authors:  N Kenawy; A Garrick; H Heimann; S E Coupland; B E Damato
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-16       Impact factor: 3.117

2.  Total regression of extensive conjunctival intraepithelial neoplasia with superficial corneal invasion treated with topical mitomycin C 0.02%.

Authors:  Marta Calatayud; Josep Badal; Laia Bisbe; Sara Martin; Javier Puig
Journal:  BMJ Case Rep       Date:  2009-12-03

3.  The clinical value of in vivo confocal microscopy for diagnosis of ocular surface squamous neoplasia.

Authors:  Y Xu; Z Zhou; Y Xu; M Wang; F Liu; H Qu; J Hong
Journal:  Eye (Lond)       Date:  2012-03-09       Impact factor: 3.775

4.  Peripunctal melanocytic nevus.

Authors:  Cindy S Hwang; Seongmu Lee; Michael T Yen
Journal:  Int Ophthalmol       Date:  2011-12       Impact factor: 2.031

5.  [New tumor onset of the plica semilunaris in advanced age].

Authors:  M Grüb; E Reinthal; J M Rohrbach
Journal:  Ophthalmologe       Date:  2006-04       Impact factor: 1.059

6.  Vesicular stomatitis virus induces apoptosis in the Wong-Kilbourne derivative of the Chang conjunctival cell line.

Authors:  Eva Gallyas; György Seprényi; Eniko Sonkoly; Yvette Mándi; Lajos Kemény; Klára Megyeri
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-11-19       Impact factor: 3.117

7.  [Analysis of ocular surface alterations following proton beam radiation in eyes with conjunctival malignant melanoma].

Authors:  H Westekemper; G Anastassiou; W Sauerwein; P Chauvel; N Bornfeld; K-P Steuhl; D Meller
Journal:  Ophthalmologe       Date:  2006-07       Impact factor: 1.059

8.  Three oncocytomas in a short space of time.

Authors:  Francis Carbonaro; Geraldine J O'Dowd; Lorna M Cottrell; Charles Diaper
Journal:  Br J Ophthalmol       Date:  2007-12       Impact factor: 4.638

9.  Blue Nevi of the Ocular Surface: Clinical Characteristics, Pathologic Features, and Clinical Course.

Authors:  Ibrahim Sayed-Ahmed; Juan Carlos Murillo; Pedro Monsalve; Jan Paul Ulloa; Maria P Fernandez; James Wong; George Elgart; Anat Galor; Sander R Dubovy; Carol L Karp
Journal:  Ophthalmology       Date:  2018-03-15       Impact factor: 12.079

Review 10.  Ultra high-resolution anterior segment optical coherence tomography in the diagnosis and management of ocular surface squamous neoplasia.

Authors:  Benjamin J Thomas; Anat Galor; Afshan A Nanji; Fouad El Sayyad; Jianhua Wang; Sander R Dubovy; Madhura G Joag; Carol L Karp
Journal:  Ocul Surf       Date:  2013-11-09       Impact factor: 5.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.